Today: 16 April 2026
Unilever share price braces for results day after Deutsche Bank downgrade flags valuation
11 February 2026
1 min read

Unilever share price braces for results day after Deutsche Bank downgrade flags valuation

London, Feb 11, 2026, 07:45 GMT — Premarket

  • Unilever finished Tuesday’s session at 5,244p, advancing 1.53%.
  • Deutsche Bank downgraded Unilever to “hold” from “buy,” sticking with its 5,150p target price. The analysts flagged valuation concerns following the stock’s recent run-up. TradingView
  • Unilever reports earnings on Feb. 12, according to .

Unilever PLC finished Tuesday’s session in London at 5,244 pence, gaining 79 pence after Deutsche Bank cut its rating on the stock, citing valuation.

The call drops just as the results window opens. The consumer goods group is set to report Thursday, but with shares already moving higher, there’s not much slack for disappointing numbers.

That’s the rub. Unilever sits firmly in the “consumer staples” camp—think soap, food, daily basics. Investors often gravitate toward it when they’re after something more stable than the broader market.

Tom Sykes at Deutsche Bank points out that shares are trading at 19 times forward 12-month earnings, carrying a 19% premium over the broader market. He’s pulled back his “buy” call, writing that the current valuation just doesn’t justify it anymore. Investing.com

According to Unilever’s investor page, Q4 and full-year 2025 results are set for release on Feb. 12, with the company scheduled to attend the CAGNY conference five days later on Feb. 17. The consensus snapshot currently on display calls for underlying sales growth of 3.5% in 2025, climbing to 4.1% for 2026. Underlying operating margin? Around 20% for 2025.

The company favors “underlying sales growth” as its go-to organic metric, which excludes impacts from currency moves and acquisitions or divestitures. In the same table, that growth splits into volume—actual units sold—and price, reflecting how much it increased prices.

The volume line is drawing the sharpest focus from traders. If volume shows strength, it points to demand—rather than prices alone—driving the move.

Margins come next. When costs creep up or promotional spending climbs, staples stocks usually take a hit fast—doesn’t matter if revenue holds steady.

It’s been a subdued stretch, though not without its hints of caution. The STOXX 600 in Europe slipped 0.07% on Tuesday, lingering just shy of its all-time peak as traders weighed company news and kept their eyes on upcoming U.S. data.

Unilever shares slid 1.62% on Monday while the FTSE 100 managed just a slight gain, then bounced back on Tuesday. Its stock has been erratic.

Another straightforward concern: the stock looks pricey relative to its fundamentals. Should Unilever fall short on volumes, margins, or cash returns, calling it “defensive” won’t shield it from a correction in valuation.

The immediate focus is Thursday’s results, plus whatever 2026 guidance the company decides to share. Then comes CAGNY on Feb. 17, where investors will be looking for sharper detail on management’s view of demand and pricing power.

Stock Market Today

  • Anthropic launches Claude Opus 4.7 amid tense AI rivalry with OpenAI
    April 16, 2026, 4:39 PM EDT. Anthropic released Claude Opus 4.7 as the competition with OpenAI intensifies. OpenAI's chief revenue officer Denise Dresser criticized Anthropic's $30 billion revenue run rate, claiming it is inflated by nearly $8 billion due to accounting methods involving revenue shares with Amazon and Google. Anthropic's rapid growth, tripling since 2025, contrasts with OpenAI's concerns about Anthropic's narrow focus on coding products and insufficient cloud compute capacity. OpenAI stresses the importance of enterprise trust and flexibility, highlighting its expanded $50 billion AWS deal and exclusive cloud platform, OpenAI Frontier. This battle underscores evolving enterprise AI dynamics as players seek broader adoption beyond developer tools.

Latest article

Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

16 April 2026
Hims & Hers Health shares rose to $26.65 Thursday after the FDA said it would reconsider restrictions on several peptides, removing 12 from a high-risk list and scheduling a July review of seven more. The move follows Hims’ March decision to stop advertising compounded GLP-1 drugs and expand branded offerings through Novo Nordisk. The company acquired a California peptide facility last year to bolster supply.
NuScale Power Stock Whipsaws After U.S. Opens Door to Nuclear Loans, Space Reactor Push

NuScale Power Stock Whipsaws After U.S. Opens Door to Nuclear Loans, Space Reactor Push

16 April 2026
NuScale Power shares jumped to $13.23 before falling back to $11.52 Thursday after the White House ordered NASA to start a space-reactor program and Energy Secretary Chris Wright said initial U.S. reactors would likely get federal loans. NuScale remains the only U.S. firm with an approved small modular reactor design but has yet to secure firm orders or financing.
SoFi Technologies Stock Rises as FedNow Instant Transfers Set Up April 29 Earnings Test

SoFi Technologies Stock Rises as FedNow Instant Transfers Set Up April 29 Earnings Test

16 April 2026
SoFi Technologies shares rose 1.5% Thursday after launching instant bank transfers via its Galileo platform, allowing money to move between SoFi and outside banks in seconds. The stock traded near $19.08 in New York. Investors await first-quarter results April 29, with SoFi guiding to $1.04 billion in adjusted net revenue and 12 cents per share in adjusted earnings.
D-Wave Quantum Stock Jumps Again as Nvidia’s Ising Launch Reignites Quantum Rally

D-Wave Quantum Stock Jumps Again as Nvidia’s Ising Launch Reignites Quantum Rally

16 April 2026
D-Wave Quantum shares climbed about 5% Thursday, extending a 22.6% surge after Nvidia launched Ising, a new AI model family for quantum computing. D-Wave traded at $21.81, up from last year’s lows, and reported 2025 revenue of $24.6 million with first-quarter 2026 bookings topping $32.8 million. The company completed its $250 million Quantum Circuits acquisition in January. Market cap stood near $8.4 billion.
Morgan Stanley stock slides as AI tax tool spooks wealth managers
Previous Story

Morgan Stanley stock slides as AI tax tool spooks wealth managers

London Stock Exchange Group (LSEG) share price jumps on Elliott stake report as buyback debate flares up
Next Story

London Stock Exchange Group (LSEG) share price jumps on Elliott stake report as buyback debate flares up

Go toTop